Esophageal and/or Gastric Varices
Conditions
Keywords
Liver cirrhosis
Brief summary
The purpose of this study was to assess whether endoscopic sclerotherapy with Fibrin Sealant was superior to ligature, with or without Polidocanol, in achieving hemostasis in bleeding esophageal varices and preventing rebleeding. Therapeutic success was defined as survival of the first seven days without clinically significant bleeding.
Interventions
DRUGFibrin Sealant
Sponsors
Baxter Healthcare Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Included in the study were patients with proven bleeding from esophageal varices due to liver cirrhosis: * with a minimum age of 18 years, * with bleeding symptoms (hematemesis, melena, hematochezia, hypotension, tachycardia) that had lasted not longer than 48 hours prior to hospital admission, * who were expected to be hospitalized for at least seven days, * who agreed to participate in the study. Randomization did not take place if another therapy was medically indicated for any reason.
Exclusion criteria
Patients were excluded from the study: * in whom introduction of an endoscope was not possible for technical reasons, * who had received an alternative endoscopic treatment to eradicate varices during the last three months (sclerotherapy, ligation), * who had proven additional fundus bleeding from varices or bleeding from a hypertensive gastropathy, * who had end stage tumor disease or end stage liver cirrhosis (Child Pugh class C with organ complications, such as hepatonephric syndrome, infected ascites etc.), * who were pregnant or breast feeding, * who had a known pulmonary disease combined with restricted lung function or right ventricular failure, * who had congenital or acquired coagulopathies of non-hepatic origin, * who were currently participating or had participated in another study during the past 30 days or had already been included in this study once, * who were treated with drugs to decrease portal vein pressure (somatostatin, somatostatin analogs, terlipressin, glycylpressin, except β-blockers and nitrates), * who had shown an allergic reaction to thrombin or aprotinin, * who had a heparin-induced thrombocytopenia Type I or Type II.
Countries
Germany
Outcome results
None listed